Information Provided By:
Fly News Breaks for October 29, 2015
GERN
Oct 29, 2015 | 09:15 EDT
After meeting with Geron's management, Oppenheimer expects a trial of the company's imetelstat to show positive signs of activity in MDS patients when data is reported, which the firm expects to be at the ASH meeting in December. The firm keeps a $5.50 price target and Outperform rating on the shares. This note corrects a previously published one that had a typo in the price target.
News For GERN From the Last 2 Days
There are no results for your query GERN